In glioma, high PD-1/PD-L1 expression in tumor cells has been correlated with poor patient prognosis through immune suppression; this has attracted great interests in antibody development preventing the association between programmed cell death protein 1 (PD-1)/PD-ligand 1 (PD-L1) [26]. The gene discussed is PDCD1; the disease is central nervous system cancer.